Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result
Breast cancer
NRG-BR002: Metastasis-directed ablation (SBRT/surgery) fails to extend PFS in oligometastatic breast cancer on 1L systemic therapy
NRG-BR002 tested metastasis-directed ablation (93% SBRT; remainder surgical resection)—a local control strategy intended to eradicate visible metastatic deposits—added to first-line systemic therapy in…
NCT02364557 - Trial result
Breast cancer
Samuraciclib + fulvestrant shows higher clinical benefit and numerically longer PFS after CDK4/6 inhibition in randomized Phase 2 breast cancer trial
Samuraciclib (CT7001) is an oral, selective CDK7 inhibitor designed to disrupt estrogen receptor-driven transcriptional programs that can sustain tumor growth after resistance to CDK4/6 inhibitors. In the three-arm,…
NCT05963984 - Trial result
Prostate cancer
Olaparib (PARP inhibitor) + Abiraterone (CYP17 AR-pathway inhibitor) Extends rPFS in Non‑BRCA mCRPC (PROpel)
Olaparib is an oral PARP inhibitor combined with abiraterone, an androgen-biosynthesis (CYP17) inhibitor, and tested in the Phase 3 double-blind PROpel trial (NCT03732820) as first-line therapy for metastatic…
NCT03732820 - Trial result
Stomach and esophageal cancer
Tislelizumab (anti–PD-1) + chemo extends OS to 17.2mo in 1L advanced ESCC with 3-year durability
Tislelizumab is an anti–PD-1 monoclonal antibody designed to limit Fcγ receptor binding on macrophages, here combined with investigator-selected platinum-based chemotherapy as first-line treatment for unresectable…
NCT03783442 - Trial result
Skin cancer (non-melanoma)
Retifanlimab (PD-1) MAIC Suggests Lower Progression Risk vs Avelumab (PD-L1) in Metastatic MCC
Retifanlimab is an anti–PD-1 monoclonal antibody, while avelumab is an anti–PD-L1 antibody; this unanchored matching-adjusted indirect comparison (MAIC) contrasted individual patient data from Phase 2 POD1UM-201…
NCT03599713 - Trial result
Multiple myeloma
MK-4002 (BCMA×CD3 trispecific T-cell engager) drives 63% ORR at 12 mg in heavily pretreated RRMM
MK-4002 (formerly HPN217) is an intravenous trispecific T-cell engager that binds BCMA on myeloma cells, CD3 on T cells, and serum albumin to extend its circulating half-life; it was evaluated in a first-in-human,…
NCT04184050 - Trial result
Lymphoma
Liso-cel (CD19 CAR-T) Delivers 100% CR/ORR With Minimal CRS/Neurotoxicity in Japanese R/R FL
Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed CAR-T cell therapy evaluated in the Japanese subgroup of the Phase 2 TRANSCEND FL study (NCT04245839) in second-line or later relapsed/refractory…
NCT04245839 - Trial result Spotlight
Acute lymphoblastic leukemia
Ponatinib (BCR-ABL TKI) + blinatumomab (CD19xCD3 BiTE) improves 24-month EFS vs imatinib-chemo in Ph+ ALL
Ponatinib is a third-generation BCR-ABL tyrosine kinase inhibitor and blinatumomab is a CD19xCD3 bispecific T-cell engager; this Phase 3 GIMEMA ALL2820/LAL2820 trial (NCT04722848) randomized frontline adult Ph+ ALL…
NCT04722848 - Trial result Spotlight
Non-small cell lung cancer
Canakinumab (IL-1β blockade) + cCRT and durvalumab consolidation hits 67% 24-mo PFS in unresectable stage III NSCLC
CHORUS (NCT04905316) tested canakinumab, an anti–interleukin-1β monoclonal antibody intended to blunt protumor inflammation, given with concurrent chemoradiotherapy (cCRT) and continued alongside anti–PD-L1…
NCT04905316 - Trial result
Uterine (endometrial) cancer
Pembrolizumab monotherapy is associated with longer time to next treatment than chemotherapy in a real-world dMMR endometrial cancer study
Pembrolizumab is an anti–PD-1 monoclonal antibody tested here as first-line (1L) chemotherapy-free monotherapy in a US Flatiron real-world retrospective cohort of dMMR/MSI-H advanced or recurrent endometrial cancer…
- Trial result Spotlight
Lymphoma
Glofitamab (CD3×CD20) + pola-R-CHP (CD79b ADC + anti-CD20 chemoimmunotherapy) drives 95% CR and 95% 24‑mo PFS in high-risk 1L DLBCL
Glofitamab is a CD3×CD20 T-cell–engaging bispecific antibody added to polatuzumab vedotin (CD79b ADC) plus R-CHP chemotherapy (rituximab, cyclophosphamide, doxorubicin, prednisone) in a multicenter Phase II frontline…
NCT05800366 - Trial result
Kidney cancer
Tobemstomig (PD-1×LAG-3) ± tiragolumab (anti-TIGIT) + axitinib adds toxicity without PFS/ORR gain in 1L ccRCC
Tobemstomig is a bispecific PD-1/LAG-3 checkpoint inhibitor evaluated with axitinib (VEGF-TKI), with or without tiragolumab (anti-TIGIT), versus pembrolizumab (anti–PD-1) + axitinib in this randomized, open-label…
NCT05805501 - Trial result Spotlight
Ovarian cancer
Sofetabart mipitecan (FRα-targeted ADC) posts 50.5% ORR and 8.1-mo mPFS in heavily pretreated HGOC—without keratopathy
Sofetabart mipitecan (Sofe-M) is an FRα-targeting antibody–drug conjugate engineered to broaden activity beyond “FRα-high only” tumors and potentially avoid the ocular toxicity seen with mirvetuximab soravtansine…
NCT07213804 - Trial result
Acute myeloid leukemia and MDS
CPX-351 (liposomal daunorubicin/cytarabine) + CD33-targeted gemtuzumab ozogamicin delivers 19% CRc in heavily pretreated R/R AML
CPX-351, a fixed-ratio liposomal formulation of daunorubicin + cytarabine, was combined with gemtuzumab ozogamicin (GO), a CD33-directed calicheamicin antibody–drug conjugate, in a Phase 2 pilot study in…
NCT03672539 - Trial result
Thyroid cancer
Selpercatinib (selective RET inhibitor) posts 53% ORR with 2-year durability in pediatric RET-altered tumors
Selpercatinib is an oral, CNS-active, highly selective RET tyrosine kinase inhibitor evaluated in the multicenter Phase I/II LIBRETTO-121 trial (NCT03899792) in children/adolescents/young adults age 0.5–21 with…
NCT03899792 - Trial result
Sarcoma and GIST
Nivolumab + cabozantinib shows feasible safety and prolonged disease stabilization in a small HIV-positive solid-tumor cohort
Nivolumab is a PD-1 immune checkpoint inhibitor and cabozantinib is a multi-kinase TKI (including VEGFR2/MET/AXL) with putative myeloid/TME-modulating effects; this multicenter Phase 1 pilot enrolled people with HIV…
NCT04514484 - New trial
Chronic lymphocytic leukemia
Phase 1b/2 roginolisib PI3K-delta inhibitor with sequential obinutuzumab and venetoclax after BTK inhibitors in CLL
Dana-Farber Cancer Institute is running a Phase 1b/2, open-label, single-arm study testing roginolisib (IOA-244), a selective, allosteric PI3K-delta inhibitor developed by iOnctura, in relapsed or refractory chronic…
NCT07847957 Exploratory - New trial
Melanoma
Randomized trial compares comprehensive margin assessment with standard pathology after melanoma surgery
The University of Nebraska is conducting a randomized study comparing two methods of examining tissue removed during wide local excision (WLE) for Stage I–II cutaneous melanoma, including acral melanoma. All…
NCT07869381 Exploratory - Trial result Spotlight
Breast cancer
Giredestrant (oral SERD) + everolimus improves PFS after CDK4/6 inhibition, with the strongest benefit in ESR1-mutated breast cancer
Giredestrant is an oral selective estrogen receptor degrader (SERD) designed to overcome ER-driven endocrine resistance, and everolimus is an oral mTOR inhibitor targeting the PI3K–AKT–mTOR pathway; the all-oral…
NCT05306340 - Trial result
Breast cancer
Ceralasertib (ATR inhibitor) + Olaparib (PARP inhibitor) hits 37.8% ORR in PARPi‑naïve BRCA‑mut HER2‑neg breast cancer
Ceralasertib is an oral ATR kinase inhibitor that amplifies replication stress and is hypothesized to resensitize tumors to PARP inhibition; here it was combined with olaparib (PARPi) in a modular Phase 1…
NCT02264678 - Trial result Spotlight
Bladder and urothelial cancer
GemBCG (intravesical gemcitabine + BCG immunostimulation) delivers 96% 6‑mo CR in BCG-exposed high‑grade NMIBC
GemBCG combines intravesical gemcitabine (a DNA synthesis–inhibiting antimetabolite chemotherapy) with intravesical BCG (live-attenuated mycobacterial immunotherapy) in an alternating schedule to intensify local…
NCT04179162 - Trial result
Bladder and urothelial cancer
TAR-200 (intravesical gemcitabine device) vs nadofaragene firadenovec: no statistically significant CR durability difference detected through 24 months in BCG-unresponsive CIS
This reconstructed individual patient data (rIPD) cross-trial analysis digitized published Kaplan–Meier duration-of-response (DoR) curves among complete responders (CR-only) from SunRISe-1 Cohort 2 (TAR-200…
NCT02773849 - Trial result Spotlight
Chronic lymphocytic leukemia
Ibrutinib (BTK inhibitor) + venetoclax (BCL-2 inhibitor) improves long-term OS/PFS in 1L CLL, with more progression-free time without grade 3/4 AEs
Fixed-duration ibrutinib-venetoclax is an all-oral BTK/BCL-2 doublet evaluated in the Phase 3 GLOW trial (NCT03462719) in older/comorbid, previously untreated CLL, randomized vs chlorambucil-obinutuzumab (n=106 vs…
NCT03462719 - Trial result
Neuroendocrine and adrenal tumors
Single ¹³¹I-MIBG (NET-targeted radiopharmaceutical) + single autologous stem cell rescue shows feasible engraftment but low response in resistant neuroblastoma
¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) is a norepinephrine transporter (NET)-avid targeted radiopharmaceutical for MIBG-avid neuroblastoma; this retrospective expanded-access experience (NCT00107289) at MSK…
NCT00107289 - Trial result
Chronic lymphocytic leukemia
Safimaltib (JNJ-67856633) MALT1 inhibitor posts 28.8% pooled ORR across heavily pretreated B-cell lymphomas and CLL, with frequent hyperbilirubinemia
Safimaltib is an oral, once-daily MALT1 (paracaspase) protease inhibitor designed to dampen B-cell receptor/NF-κB signaling and was evaluated in a multi-center Phase 1 dose-escalation/expansion study in…
NCT03900598 - Trial result Spotlight
Lymphoma
Pembrolizumab-GVD followed by autologous transplantation shows 91% five-year PFS in relapsed/refractory classical Hodgkin lymphoma
Pembrolizumab-GVD combines pembrolizumab (anti–PD-1) with gemcitabine/vinorelbine/liposomal doxorubicin chemotherapy as PET-adaptive salvage to bridge transplant-eligible relapsed/refractory classical Hodgkin…
NCT03618550 - Trial result
Lymphoma
Favezelimab (anti–LAG-3) + pembrolizumab (PD-1) reports 83% ORR in PD-1–naive R/R cHL; development discontinued
Favezelimab (MK-4280) is an anti–LAG-3 monoclonal antibody designed to deepen checkpoint blockade when combined with pembrolizumab (anti–PD-1); this Phase 1/2 MK-4280-003 cohort enrolled anti–PD-1–naive…
NCT03598608 - Trial result
Non-small cell lung cancer
CAN-2409 + valacyclovir reports 14.3-month median OS in treated NSCLC patients; 24.5 months in a selected per-protocol group
Aglatimagene besadenovec (CAN-2409) is a replication-defective adenoviral vector encoding HSV-thymidine kinase, designed to trigger immunogenic tumor cell death after exposure to valacyclovir while patients continue…
NCT04495153 - Trial result
Multiple myeloma
Forimtamig (GPRC5D×CD3 2:1 bispecific) posts 72% ORR at optimized SC dosing—but toxicity caps escalation in RRMM
Forimtamig is a subcutaneous GPRC5D×CD3 T-cell–engaging bispecific antibody using a novel 2:1 format, evaluated in a Phase 1 dose-escalation/backfill study in relapsed/refractory multiple myeloma (RRMM; NCT04557150).…
NCT04557150 - Trial result
Head and neck cancer
Setanaxib + pembrolizumab misses its tumor-shrinkage endpoint but shows exploratory survival signals in CAF-rich head and neck cancer
Setanaxib (GKT137831) is an oral dual NADPH oxidase (NOX)1/NOX4 inhibitor intended to reduce reactive oxygen species (ROS)–driven, fibroblast-associated immune suppression, and it was combined with pembrolizumab…
NCT05323656
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.